A detailed history of Wells Fargo & Company transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 7,501 shares of ORMP stock, worth $18,752. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,501
Previous 4,501 66.65%
Holding current value
$18,752
Previous $10,000 110.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$2.18 - $3.58 $6,540 - $10,740
3,000 Added 66.65%
7,501 $21,000
Q3 2023

Nov 13, 2023

SELL
$2.51 - $3.55 $3,764 - $5,325
-1,500 Reduced 25.0%
4,501 $11,000
Q2 2023

Aug 15, 2023

BUY
$2.12 - $4.47 $4,030 - $8,497
1,901 Added 46.37%
6,001 $21,000
Q1 2023

May 12, 2023

SELL
$1.93 - $13.1 $116,923 - $793,624
-60,582 Reduced 93.66%
4,100 $8,000
Q4 2022

Feb 13, 2023

BUY
$6.21 - $12.03 $33,223 - $64,360
5,350 Added 9.02%
64,682 $778,000
Q3 2022

Nov 14, 2022

BUY
$4.6 - $9.91 $247,277 - $532,721
53,756 Added 964.06%
59,332 $384,000
Q2 2022

Aug 12, 2022

SELL
$3.72 - $9.0 $459,364 - $1.11 Million
-123,485 Reduced 95.68%
5,576 $26,000
Q1 2022

May 16, 2022

BUY
$8.19 - $13.89 $312,030 - $529,195
38,099 Added 41.88%
129,061 $1.12 Million
Q4 2021

Feb 14, 2022

BUY
$12.98 - $29.75 $1.07 Million - $2.45 Million
82,213 Added 939.68%
90,962 $1.3 Million
Q3 2021

Nov 15, 2021

BUY
$12.13 - $23.82 $42,236 - $82,941
3,482 Added 66.11%
8,749 $192,000
Q2 2021

Aug 16, 2021

BUY
$8.34 - $14.59 $15,987 - $27,969
1,917 Added 57.22%
5,267 $71,000
Q1 2021

May 13, 2021

BUY
$4.22 - $11.33 $2,110 - $5,665
500 Added 17.54%
3,350 $34,000
Q3 2020

Nov 05, 2020

SELL
$2.58 - $4.16 $4,063 - $6,552
-1,575 Reduced 35.59%
2,850 $7,000
Q2 2020

Aug 13, 2020

BUY
$2.87 - $4.12 $1,650 - $2,369
575 Added 14.94%
4,425 $16,000
Q1 2020

May 14, 2020

BUY
$2.6 - $5.5 $10,010 - $21,175
3,850 New
3,850 $12,000

Others Institutions Holding ORMP

About ORAMED PHARMACEUTICALS INC.


  • Ticker ORMP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,100
  • Market Cap $97.1M
  • Description
  • Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...
More about ORMP
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.